Undiagnosed Diseases Gene Function Research (R21) | Apply Online

Opportunity Summary:

The Undiagnosed Diseases Gene Function Research (R21) opportunity (Funding Opportunity Number RFA-RM-14-005) is an NIH exploratory/developmental grant designed to speed up early-stage research on extremely rare, newly identified diseases by focusing on what specific gene variants actually do in living systems. The central idea is to pair investigators who can run solid gene function experiments with the clinical and genomic discovery pipeline of the Undiagnosed Diseases Network (UDN), which expanded upon the earlier NIH Intramural Undiagnosed Diseases Program (NIH UDP). In practical terms, the grant supports projects that move beyond simply naming a candidate variant and instead test how that variant alters biology, whether at the level of genetics, protein function and biochemical pathways, cellular physiology, or broader disease mechanisms (pathophysiology). The goal is to convert a suspected gene-disease link into convincing functional evidence that clarifies disease cause, supports diagnosis, and points toward potential therapeutic directions.

The scientific scope emphasizes functional follow-up on variants and conditions emerging from the UDN, meaning applications are expected to be tightly connected to real unsolved patient cases and newly diagnosed disease entities. Projects are considered responsive when they propose credible experimental approaches to explain how an identified gene variant leads to the observed clinical presentation. That can include molecular and cellular studies, biochemical assays, model organism work, pathway analyses, and related strategies that establish mechanism. The opportunity reflects the view that modern diagnosis of rare disease increasingly depends on combining sequencing and genomic interpretation with functional testing and, where appropriate, metabolic studies. By funding this kind of work, NIH aims to improve the strength of evidence behind rare disease diagnoses and simultaneously grow basic knowledge about human biology and disease pathways that may have relevance beyond a single disorder.

This funding announcement uses the NIH R21 mechanism, which is meant for exploratory or developmental research where investigators are pursuing promising ideas that may not yet have the extensive preliminary data expected for larger awards. The program sits within the NIH “Common Fund,” which supports cross-cutting initiatives intended to have unusually high impact across biomedical research rather than being confined to one institute’s disease area. In other words, while the immediate focus is on very rare and often unique conditions, the broader intent is to produce insights, methods, and validated gene-function relationships that can strengthen rare disease science overall and potentially illuminate pathways relevant to more common conditions too.

From an administrative and eligibility standpoint, this is a discretionary NIH grant opportunity in the health category (CFDA 93.310, Trans-NIH Research Support). It does not require cost sharing or matching. The estimated total funding listed is $1,000,000, with an award ceiling of $150,000 per award (as stated in the source data). A wide range of applicant organizations are eligible, including state and local governments, public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (other than small businesses), and small businesses. The eligibility language is broad and also explicitly includes various institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and AANAPISI institutions. Importantly, non-U.S. entities are eligible to apply, including foreign organizations and foreign institutions, and foreign components as defined by NIH policy are allowed, as are non-domestic components of U.S. organizations.

Key timing details in the announcement show it was posted and created on April 18, 2014, with an original and current closing date of June 23, 2014, and an archive date of July 24, 2014. The sponsoring agency is the National Institutes of Health. The full announcement was provided through the NIH grants guide (via the link in the notice). For technical issues accessing the announcement, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.

Overall, this opportunity is best understood as a targeted push to close the gap between “we found a candidate variant in a patient” and “we can prove how that variant causes disease.” By incentivizing collaboration with the UDN and paying specifically for functional and mechanistic work, the R21 aims to turn rare, difficult-to-diagnose cases into well-characterized disorders with clearer molecular explanations, more confident diagnoses, and a stronger foundation for future translational efforts.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Exploratory Clinical Trials of Mind and Body Interventions for NCCAM High Priority Research Topics (R34)

Previous opportunity: Civic Education through English Language in Georgia

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA RM 14 005

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA RM 14 005) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 14 005", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.